<unk>  acts on M2 and M3 subtypes of muscarinic receptors whereas older antimuscarinic treatments for overactive bladder act more specifically on M3 receptors.<unk> , although it acts on all types of receptors, has fewer side effects than oxybutynin (M3 and M1 selective, but more so in the parotid than in the bladder) as<unk>  targets the bladder more than other areas of the body. This means that less drug needs to be given daily (due to efficient targeting of the bladder) and so there are fewer side effects.
Tolterodine
Ingenol mebutate
Nandrolone furylpropionate
Fesoterodine
Androstanolone propionate
Nandrolone phenylpropionate
Drostanolone propionate
Nandrolone propionate